Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.68 |
| ▸ | HPGD | P15428 | 2/20 | 0.68 |
| ▸ | USP2 | O75604 | 1/20 | 0.68 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.68 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.51 |
| ▸ | CA12 | O43570 | 1/20 | 0.49 |
| ▸ | ALPL | P05186 | 1/20 | 0.49 |
| ▸ | GCGR | P47871 | 1/20 | 0.48 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.47 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | F7 | P08709 | 1/20 | 0.43 |
| ▸ | F3 | P13726 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28281813 | 0.82 | KDM4E (0.70) | KDM4EHPGDUSP2HSD17B10CA12 | |
| SCHEMBL308253 | 0.82 | KDM4E (0.69) | KDM4EHPGDUSP2HSD17B10NOTUM | |
| SCHEMBL31518266 | 0.81 | KDM4E (0.46) | KDM4EHPGDUSP2HSD17B10NOTUM | |
| SCHEMBL3154080 | 0.81 | KDM4E (1.00) | KDM4EHPGDUSP2HSD17B10ALPL | |
| Hydrochloric Acid SCHEMBL30729495 | 0.80 | KDM4E (0.45) | KDM4EHPGDUSP2HSD17B10NOTUM | |
| SCHEMBL10445823 | 0.80 | KDM4E (0.57) | KDM4EHPGDUSP2HSD17B10NOTUM | |
| SCHEMBL8341738 | 0.80 | KDM4E (0.67) | KDM4EHPGDUSP2HSD17B10NOTUM | |
| Hydrochloric Acid SCHEMBL6335114 | 0.80 | KDM4E (0.67) | KDM4EHPGDUSP2HSD17B10NOTUM | |
| SCHEMBL8663770 | 0.79 | MAPT (0.54) | KDM4EHPGDUSP2HSD17B10GCGR | |
| SCHEMBL9750144 | 0.79 | KDM4E (0.63) | KDM4EHPGDUSP2HSD17B10PTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230118233-A1 | PRC1 INHIBITORS AND METHODS OF TREATMENT THEREWITH | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2023-04-20 | — | — | US | disclosed |
| US-11319302-B2 | PRC1 inhibitors and methods of treatment therewith | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2022-05-03 | — | — | US | disclosed |
| US-20200039963-A1 | PRC1 INHIBITORS AND METHODS OF TREATMENT THEREWITH | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2020-02-06 | — | — | US | disclosed |
| US-20040082079-A1 | Low affinity screening method | GRAFFINITY PHARMACEUTICALS AG. (DE) | 2004-04-29 | — | — | US | disclosed |
| EP-1360489-A1 | LOW AFFINITY SCREENING METHOD | Graffinity Pharmaceuticals Aktiengesellschaft (DE) | 2003-11-12 | — | — | EP | disclosed |
| WO-2002063299-A1 | LOW AFFINITY SCREENING METHOD | GRAFFINITY PHARMACEUTICALS AG (DE) | 2002-08-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11319302-B2 | PRC1 inhibitors and methods of treatment therewith | BMI1, EZH2, CBX3 | KDM4E 154/4885HPGD 3239/4885USP2 574/4885 |
| US-20200039963-A1 | PRC1 INHIBITORS AND METHODS OF TREATMENT THEREWITH | BMI1, EZH2, CBX3 | KDM4E 154/4885HPGD 3239/4885USP2 574/4885 |
| US-20230118233-A1 | PRC1 INHIBITORS AND METHODS OF TREATMENT THEREWITH | BMI1, EZH2, CBX3 | KDM4E 154/4885HPGD 3239/4885USP2 574/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.